As Chinese and Indian Markets Expand, Young American Drug Outfits Should Hold Onto Ex-U.S. Rights, Says Genzyme Leader
This article was originally published in PharmAsia News
Executive Summary
BOSTON - Despite conventional wisdom and Wall Street's old-fashioned point of view, young American companies starting out should think long and hard before giving up ex-U.S. rights to their discoveries, the top executives of Massachusetts biotechs Genzyme and Biogen Idec advise